Naturally occurring hormone and antioxidant that has numerous biological effects.
High Dosage Melatonin 60mg in easy-to-swallow capsules.
The body’s melatonin production is easily disrupted by today’s lifestyle. If you use a computer, television, smart phone, or other screen device in the evening, it can interfere with melatonin production. Even ordinary light bulbs can be a problem.
If you’re in an office all day and don’t get enough natural light exposure during waking hours, your body is missing important signals needed to produce sufficient melatonin.
Each bottle contains 60x 60mg melatonin Capsules
All Scientific Health Solution Products are third-party tested.

What is melatonin and how does it work?

Melatonin is a hormone that your brain produces in response to darkness. It helps with the timing of your circadian rhythms (24-hour internal clock) and with sleep. Being exposed to light at night can block melatonin production. Research suggests that melatonin plays other important roles in the body beyond sleep. Melatonin is so much more than just sleep, Although sleep helps your immune system and strengthens your body. The high levels of Melatonin have been studied for many additional health benefits. The above is quoted from Scientific Health Solutions

There is evidence that high dose (100-500mg) melatonin protects healthy cells from radiation and actually sensitizes cancer cells to radiation, and synergizes with anti-hormone therapy. Usually it is started at 60mg at night then increased as tolerated to about 1/3 in the morning and 2/3rds at night. The exception is radiation protection- there it is best to take it a hour or two before. Melatonin has a half life that is long at night- but much shorter during the day. Some people find that it does not affect their sleep or wakefulness, others find they are sleepy in the daytime, and others find it harder to sleep- some even sleep very well with 2mg melatonin but poorly with 300mg- it is individual. https://www.hilarispublisher.com/open-access/melatonininduced-oncostasis-mechanisms-and-clinical-relevance-2329-6771-S1-006.pdf The paper "Melatonin-Induced Oncostasis: Mechanisms and Clinical Relevance" delves into the multifaceted role of melatonin in cancer prevention and treatment. This comprehensive review synthesizes current research on how melatonin, a hormone primarily known for regulating sleep-wake cycles, exhibits oncostatic (cancer-inhibiting) properties through various biological mechanisms. ### Key Points and Mechanisms 1. **Antioxidant Properties:** - Melatonin is a potent antioxidant that scavenges free radicals and upregulates antioxidant enzymes. This reduces oxidative stress, which is a known contributor to cancer development. By protecting cellular DNA from oxidative damage, melatonin helps in maintaining genomic stability. 2. **Regulation of Cell Cycle and Apoptosis:** - The paper highlights melatonin's ability to modulate the cell cycle and induce apoptosis (programmed cell death) in cancer cells. It achieves this by influencing the expression of genes involved in cell proliferation and survival, such as p53, Bcl-2, and Bax. This selective induction of apoptosis in cancer cells while sparing normal cells is a crucial aspect of its therapeutic potential. 3. **Anti-Angiogenic Effects:** - Melatonin inhibits angiogenesis, the process by which new blood vessels form from pre-existing ones. This is significant because tumors require a blood supply to grow and metastasize. Melatonin downregulates pro-angiogenic factors like VEGF (vascular endothelial growth factor), thereby starving the tumor of nutrients and oxygen. 4. **Immune System Modulation:** - The hormone enhances the immune system's ability to detect and destroy cancer cells. It boosts the activity of natural killer (NK) cells and cytotoxic T lymphocytes, which are essential components of the immune response against tumors. 5. **Interaction with Estrogen Receptors:** - Melatonin exhibits anti-estrogenic effects, which is particularly relevant for hormone-dependent cancers such as breast cancer. It downregulates estrogen receptor expression and inhibits the local synthesis of estrogen within the tumor microenvironment, thereby reducing estrogen-driven tumor growth. 6. **Synergistic Effects with Conventional Therapies:** - The paper discusses how melatonin can enhance the efficacy of conventional cancer treatments like chemotherapy and radiotherapy. It can sensitize cancer cells to these treatments, reduce their side effects, and improve overall patient outcomes. ### Clinical Relevance The clinical relevance of melatonin in oncology is underscored by various studies and clinical trials cited in the paper. These studies demonstrate that melatonin supplementation can improve survival rates, reduce tumor progression, and enhance the quality of life for cancer patients. The paper advocates for the integration of melatonin into standard cancer treatment protocols, given its low toxicity and multifaceted oncostatic properties. Other papers to review: https://www.mdpi.com/1420-3049/23/3/518 The paper "Melatonin and Cancer Hallmarks" explores the multifaceted role of melatonin, a hormone primarily known for regulating sleep-wake cycles, in the context of cancer biology. The authors delve into how melatonin influences various hallmarks of cancer, which are the distinct and complementary capabilities that enable tumor growth and metastatic dissemination. Key points discussed in the paper include: 1. **Antioxidant Properties**: Melatonin's potent antioxidant capabilities help in reducing oxidative stress, which is a significant factor in cancer progression. By scavenging free radicals, melatonin protects cellular components from damage, thereby potentially inhibiting the initiation and progression of cancer. 2. **Anti-proliferative Effects**: The hormone has been shown to inhibit cell proliferation in various cancer cell lines. This is achieved through the modulation of cell cycle regulatory proteins, leading to cell cycle arrest and reduced tumor growth. 3. **Induction of Apoptosis**: Melatonin promotes apoptosis, or programmed cell death, in cancer cells. This is crucial for eliminating malignant cells and preventing tumor development. The paper details the pathways through which melatonin induces apoptosis, including the activation of pro-apoptotic proteins and suppression of anti-apoptotic proteins. 4. **Anti-angiogenic Properties**: Angiogenesis, the formation of new blood vessels, is essential for tumor growth and metastasis. Melatonin inhibits angiogenesis by downregulating pro-angiogenic factors and upregulating anti-angiogenic factors, thus starving the tumor of necessary nutrients and oxygen. 5. **Immune System Modulation**: The hormone enhances the immune system's ability to recognize and destroy cancer cells. It modulates the activity of various immune cells, including natural killer cells and T lymphocytes, which play a critical role in the body's defense against cancer. 6. **Inhibition of Metastasis**: Melatonin interferes with the metastatic process by inhibiting the migration and invasion of cancer cells. This is achieved through the modulation of signaling pathways and the expression of molecules involved in cell adhesion and motility. 7. **Epigenetic Modulation**: The paper also discusses how melatonin can influence gene expression through epigenetic mechanisms, such as DNA methylation and histone modification, which can suppress oncogene expression and activate tumor suppressor genes. https://www.mdpi.com/2076-3271/11/1/9 The authors review preclinical studies that demonstrate melatonin's efficacy in inhibiting melanoma cell proliferation and inducing apoptosis. These studies suggest that melatonin can downregulate the expression of pro-survival genes and upregulate pro-apoptotic genes, thereby tipping the balance towards cell death in melanoma cells. Additionally, melatonin's antioxidant properties help mitigate the oxidative stress that often accompanies cancer progression. Clinical studies are also examined, with a focus on melatonin's potential to enhance the effectiveness of conventional therapies. The paper highlights instances where melatonin, when used in conjunction with chemotherapy or radiation, improved patient outcomes by sensitizing melanoma cells to these treatments and reducing their side effects. This synergistic effect is attributed to melatonin's ability to modulate the tumor microenvironment and enhance the immune system's ability to target cancer cells. Furthermore, the paper discusses the pharmacokinetics of melatonin, noting its high safety profile, low toxicity, and ease of administration. These attributes make melatonin an attractive candidate for repurposing as an adjuvant therapy in melanoma treatment. The authors also address potential challenges, such as the need for standardized dosing regimens and the identification of biomarkers to predict patient response to melatonin therapy. In conclusion, the paper posits that melatonin holds promise as a repurposed drug for melanoma treatment, offering a multifaceted approach to combat this aggressive cancer. The authors call for further clinical trials to validate the efficacy and safety of melatonin in melanoma patients and to establish its role in the standard treatment protocols. They emphasize the importance of a multidisciplinary approach, integrating melatonin with existing therapies to enhance overall treatment outcomes and improve the quality of life for melanoma patients. https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.e22514 The study aimed to determine the optimal dose of melatonin for paediatric patients suffering from relapsed solid tumors. The primary objectives included assessing the safety, tolerability, and pharmacokinetics of melatonin in this patient population. Secondary objectives focused on preliminary efficacy and potential biological activity. Participants received escalating doses of melatonin, with close monitoring for adverse effects and response to treatment. The study found that melatonin was generally well-tolerated, with manageable side effects. https://www.naturalmedicinejournal.com/journal/overview-melatonin-and-breast-cancer https://pubmed.ncbi.nlm.nih.gov/28420185/ The paper explores the multifaceted role of melatonin, a hormone primarily known for regulating sleep-wake cycles, in cancer prevention and therapy. Melatonin exhibits a wide range of anti-cancer properties that make it a potent agent against various stages of cancer development, including initiation, progression, and metastasis. **Inhibition of Initiation:** Melatonin has been found to possess antioxidant properties that help in neutralizing free radicals, thereby reducing oxidative stress and DNA damage, which are critical factors in the initiation of cancer. The hormone also enhances the efficiency of DNA repair mechanisms and modulates the activity of enzymes involved in detoxification processes, further contributing to its protective role against cancer initiation. **Inhibition of Progression:** Once cancer has been initiated, melatonin continues to exert its effects by inhibiting cell proliferation and promoting apoptosis (programmed cell death) in cancer cells. It interferes with various signaling pathways that are crucial for cancer cell survival and growth, such as the PI3K/Akt and MAPK pathways. Additionally, melatonin has been shown to modulate the expression of genes involved in cell cycle regulation, thereby preventing the uncontrolled division of cancer cells. **Inhibition of Metastasis:** Melatonin also plays a significant role in preventing metastasis, the process by which cancer cells spread to other parts of the body. It inhibits the migration and invasion of cancer cells by downregulating the expression of molecules involved in these processes, such as matrix metalloproteinases (MMPs) and adhesion molecules. Furthermore, melatonin has anti-angiogenic properties, meaning it can prevent the formation of new blood vessels that supply nutrients to tumors, thereby inhibiting their growth and spread. The paper highlights the potential of melatonin as an adjuvant therapy in cancer treatment due to its ability to enhance the efficacy of conventional treatments like chemotherapy and radiation while reducing their side effects. Melatonin's low toxicity and ability to target multiple pathways make it a promising candidate for comprehensive cancer management. In conclusion, melatonin is presented as a versatile and potent anti-cancer agent that can inhibit the initiation, progression, and metastasis of cancer through various mechanisms. Its potential benefits in cancer therapy warrant further research and clinical trials to fully harness its therapeutic potential. https://pubmed.ncbi.nlm.nih.gov/9247204/ The paper reviews the potential of melatonin, a hormone primarily known for regulating sleep, as an oncostatic (cancer-inhibiting) agent. It discusses various studies and clinical trials that suggest melatonin may inhibit cancer cell growth, enhance the effectiveness of conventional cancer treatments, and improve the overall prognosis for cancer patients. The mechanisms proposed include melatonin's antioxidant properties, its ability to modulate the immune system, and its role in regulating cell cycle and apoptosis (programmed cell death). While promising, the paper also highlights the need for further research to fully understand melatonin's efficacy and safety as a cancer treatment. https://pubmed.ncbi.nlm.nih.gov/16647824/ The paper explores the relationship between the estrogen-signaling pathway and the oncostatic (cancer-inhibiting) effects of melatonin in breast cancer. It highlights how melatonin can interfere with estrogen signaling, which is crucial in the development and progression of breast cancer. By modulating this pathway, melatonin may help inhibit the growth of estrogen-responsive breast cancer cells, suggesting its potential as a therapeutic agent. https://ojs.omniscient.sg/index.php/TrendsinOncology/article/view/988/997 The study investigates the effects of administering a very high dose of melatonin (1000 mg/day) to patients with advanced cancer who have not responded to previous palliative treatments. The preliminary results suggest that this high-dose melatonin regimen may offer some therapeutic benefits, potentially improving the quality of life and clinical outcomes for these patients. However, further research is needed to confirm these findings and to better understand the mechanisms involved. https://pubmed.ncbi.nlm.nih.gov/15813897/ The paper delves into the complex interplay between melatonin, a hormone primarily produced by the pineal gland, and estrogen, a key hormone involved in the development and progression of breast cancer. The authors explore how melatonin can influence estrogen signaling pathways, potentially offering a protective effect against breast cancer. Melatonin is known for its role in regulating circadian rhythms, but it also possesses anti-carcinogenic properties. The paper highlights several mechanisms through which melatonin may exert its effects on breast cancer cells. One of the primary mechanisms discussed is melatonin's ability to modulate estrogen receptor (ER) activity. Melatonin can bind to ERs, thereby inhibiting the estrogen-induced proliferation of breast cancer cells. This interaction suggests that melatonin could act as a natural anti-estrogenic agent. Additionally, the paper examines how melatonin influences the expression of genes involved in estrogen synthesis and metabolism. By downregulating aromatase, the enzyme responsible for converting androgens to estrogens, melatonin reduces the local production of estrogen within breast tissue. This reduction in estrogen levels can decrease the growth stimulus for ER-positive breast cancer cells. The paper also explores the antioxidant properties of melatonin, which can mitigate oxidative stress, a known factor in cancer development. Melatonin's ability to scavenge free radicals and enhance the activity of antioxidant enzymes contributes to its protective role against breast cancer. Furthermore, the authors discuss the potential therapeutic applications of melatonin in breast cancer treatment. They suggest that melatonin could be used as an adjuvant therapy alongside conventional treatments like chemotherapy and radiation. Its low toxicity and ability to enhance the efficacy of these treatments make it a promising candidate for integrative cancer therapy. In conclusion, the paper provides a comprehensive overview of the multifaceted interactions between melatonin and estrogen in the context of breast cancer. It underscores the potential of melatonin as a protective agent and a therapeutic adjunct in the management of breast cancer, warranting further clinical investigation. https://pubmed.ncbi.nlm.nih.gov/30563247/ The paper explores the potential role of melatonin, a hormone primarily known for regulating sleep-wake cycles, in enhancing the anticancer effects of pleiotropic drugs. Pleiotropic drugs are medications that have multiple effects on different physiological pathways and are often used in cancer treatment due to their broad-spectrum activity. The authors delve into the molecular mechanisms by which melatonin may augment the efficacy of these drugs, focusing on its antioxidant, anti-inflammatory, and immune-modulating properties. Melatonin is highlighted for its ability to modulate various signaling pathways involved in cancer progression, such as the inhibition of the NF-κB pathway, reduction of oxidative stress, and enhancement of apoptosis (programmed cell death) in cancer cells. Additionally, melatonin's role in regulating circadian rhythms is discussed as a factor that may influence the timing and effectiveness of cancer therapies. The paper reviews preclinical and clinical studies that have investigated the synergistic effects of combining melatonin with different pleiotropic drugs, including chemotherapy agents and targeted therapies. Results from these studies suggest that melatonin not only improves the therapeutic outcomes but also reduces the side effects associated with conventional cancer treatments. In conclusion, the authors propose that incorporating melatonin into cancer treatment regimens could be a promising strategy to enhance the anticancer potential of pleiotropic drugs. They call for further research to better understand the optimal dosing, timing, and combination strategies to maximize the benefits of melatonin in cancer therapy. https://pubmed.ncbi.nlm.nih.gov/30386380/ Melatonin, a hormone primarily produced by the pineal gland, has shown promise as an anti-tumor agent in hormone-dependent cancers. Research indicates that melatonin can inhibit cancer cell growth, induce apoptosis (programmed cell death), and enhance the effectiveness of conventional cancer treatments. Its anti-cancer properties are particularly evident in cancers such as breast and prostate cancer, where hormone regulation plays a significant role. Melatonin's potential as a therapeutic agent offers a complementary approach to existing treatments, potentially improving patient outcomes. https://pubmed.ncbi.nlm.nih.gov/28415828/ The study explores the potential role of melatonin, a hormone primarily known for regulating sleep, in the prevention and treatment of cancer. Research indicates that melatonin may have anti-cancer properties, including the ability to inhibit tumor growth, reduce metastasis, and enhance the efficacy of conventional cancer treatments. The study suggests that melatonin's antioxidant, anti-inflammatory, and immune-modulating effects contribute to its potential as a complementary therapy in oncology. https://pubmed.ncbi.nlm.nih.gov/28933733/ The study titled "Melatonin Decreases Glucose Metabolism in Prostate Cancer Cells: A 13C Stable Isotope-Resolved Metabolomic Study" investigates how melatonin affects glucose metabolism in prostate cancer cells. The research uses 13C stable isotope-resolved metabolomics to track changes and demonstrates that melatonin significantly reduces glucose metabolism in these cells, potentially impacting cancer cell growth and survival. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425818/ The paper "The melatonin immunomodulatory actions in radiotherapy" explores how melatonin can modulate the immune response in the context of radiotherapy. It highlights melatonin's potential to enhance the therapeutic effects of radiotherapy while mitigating its adverse side effects. The study discusses the mechanisms by which melatonin influences immune cells, reduces inflammation, and protects normal tissues from radiation-induced damage. Overall, the findings suggest that melatonin could be a valuable adjunct in radiotherapy to improve patient outcomes. https://pubmed.ncbi.nlm.nih.gov/32726912/ 1. **Introduction to Melatonin**: The paper discusses melatonin, a hormone primarily known for regulating sleep-wake cycles, and its emerging role in cancer therapy. 2. **Radio-Sensitization**: Melatonin has been identified as a potential radio-sensitizer, meaning it can enhance the effectiveness of radiation therapy in treating cancer. 3. **Mechanisms of Action**: The paper outlines several mechanisms by which melatonin exerts its radio-sensitizing effects, including: - **Antioxidant Properties**: Melatonin reduces oxidative stress, which can help protect normal cells while making cancer cells more susceptible to radiation. - **Modulation of Signaling Pathways**: It influences various cellular signaling pathways that control cell survival, proliferation, and apoptosis (programmed cell death). - **DNA Repair Inhibition**: Melatonin can inhibit the repair of DNA damage in cancer cells caused by radiation, thereby enhancing the cytotoxic effects of the treatment. 4. **Preclinical and Clinical Evidence**: The paper reviews both preclinical studies (in vitro and animal models) and clinical trials that demonstrate the efficacy of melatonin as a radio-sensitizer in different types of cancer. 5. **Safety and Side Effects**: Melatonin is highlighted as having a favorable safety profile with minimal side effects, making it a promising adjunct to conventional cancer therapies. 6. **Future Directions**: The authors suggest further research to optimize dosing regimens, understand the molecular mechanisms in greater detail, and conduct large-scale clinical trials to confirm the benefits of melatonin in cancer radiotherapy. https://www.mdpi.com/1422-0067/23/15/8122 The paper explores the multifaceted role of melatonin in the context of COVID-19, particularly focusing on its potential to regulate viral phase separation and epitranscriptomics, which are crucial in understanding the long-term effects of the disease, known as Post-Acute Sequelae of COVID-19 (PASC). **Introduction:** The study begins by providing an overview of COVID-19 and its causative agent, SARS-CoV-2. It highlights the global impact of the pandemic and the emergence of PASC, a condition characterized by persistent symptoms and complications following acute COVID-19 infection. The introduction sets the stage for discussing melatonin, a hormone known for its regulatory roles in circadian rhythms and its potential therapeutic effects in viral infections. **Melatonin and Viral Phase Separation:** The paper delves into the concept of viral phase separation, a process where viral proteins and RNA form distinct liquid-like compartments within the host cell. This phase separation is crucial for viral replication and pathogenesis. The authors propose that melatonin can interfere with this process, thereby inhibiting viral replication. They discuss the molecular mechanisms through which melatonin can disrupt viral phase separation, including its antioxidant properties and its ability to modulate cellular signaling pathways. **Epitranscriptomics and Melatonin:** Epitranscriptomics refers to the chemical modifications of RNA molecules that can influence their function and stability. The paper explores how SARS-CoV-2 can hijack the host's epitranscriptomic machinery to enhance its replication and evade immune responses. Melatonin is proposed to play a role in regulating these RNA modifications, thereby mitigating the virus's ability to manipulate the host cell. The authors discuss specific RNA modifications, such as N6-methyladenosine (m6A), and how melatonin can influence these modifications to counteract viral strategies. **Melatonin in Post-Acute Sequelae of COVID-19:** The study then shifts its focus to PASC, a condition affecting a significant number of COVID-19 survivors. The authors review the symptoms and potential mechanisms underlying PASC, including chronic inflammation, immune dysregulation, and persistent viral reservoirs. They propose that melatonin, with its anti-inflammatory and immunomodulatory properties, could be a valuable therapeutic agent in managing PASC. The paper discusses clinical evidence and ongoing trials investigating the use of melatonin in COVID-19 and its long-term effects. **Conclusion:** In conclusion, the paper emphasizes the potential of melatonin as a multifaceted therapeutic agent in the fight against COVID-19 and its long-term sequelae. By regulating viral phase separation and epitranscriptomics, melatonin could inhibit viral replication and mitigate the chronic symptoms associated with PASC. The authors call for further research to validate these findings and explore the clinical applications of melatonin in COVID-19 treatment.

Unlock Full Catalog